This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in JAMA  Topic Collections  • Psychiatry  • Adverse Effects  • Alert me on articles by topic

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: We have 2 concerns about the study by Dr Rosenheck and colleagues.¹ First, the average dosages of olanzapine (14.1 mg/d) and haloperidol (13.6 mg/d) do not reflect similar levels of dopamine D₂ receptor occupancy in each treatment group: about 75% for olanzapine and about 90% for haloperidol.² Although the dosages that the authors used are common in practice, they do not reflect optimal dosing for haloperidol. Given the relationship between dopaminergic neurotransmission and extrapyramidal symptoms and aspects of cognitive and motor functioning,³ differences in dopamine D₂ receptor occupancy could partially explain the small advantages found in favor of olanzapine.

Second, all patients assigned to haloperidol received prophylactic benztropine mesylate, which may negatively modify the expression of tardive dyskinesia⁴ and may have a negative influence on cognitive functioning.

Comparing olanzapine with optimally dosed haloperidol might shift the balance even more in favor of haloperidol. Such lower doses of . . . [Full Text of this Article]

Lieuwe de Haan, MD, PhD
Academic Medical Centre
Amsterdam, the Netherlands

Nico van Beveren, MD
Erasmus University Medical Centre
Rotterdam, the Netherlands

RELATED ARTICLES

Olanzapine vs Haloperidol for Treatment of Schizophrenia
Jan Volavka and Leslie Citrome
JAMA. 2004;291(9):1064.
EXTRACT | FULL TEXT  

Olanzapine vs Haloperidol for Treatment of Schizophrenia
William M. Glazer
JAMA. 2004;291(9):1064-1065.
EXTRACT | FULL TEXT  

Olanzapine vs Haloperidol for Treatment of Schizophrenia
Mo Amin and Vijay S. Shukla
JAMA. 2004;291(9):1065.
EXTRACT | FULL TEXT  

Olanzapine vs Haloperidol for Treatment of Schizophrenia
Michal Kunz
JAMA. 2004;291(9):1065.
EXTRACT | FULL TEXT  

Olanzapine vs Haloperidol for Treatment of Schizophrenia—Reply
Robert Rosenheck, Deborah Perlick, Stephen Bingham, and Joseph Collins
JAMA. 2004;291(9):1065-1066.
EXTRACT | FULL TEXT  

Effectiveness and Cost of Olanzapine and Haloperidol in the Treatment of Schizophrenia: A Randomized Controlled Trial
Robert Rosenheck, Deborah Perlick, Stephen Bingham, Wen Liu-Mares, Joseph Collins, Stuart Warren, Douglas Leslie, Edward Allan, E. Cabrina Campbell, Stanley Caroff, June Corwin, Lori Davis, Richard Douyon, Lawrence Dunn, Denise Evans, Ede Frecska, John Grabowski, David Graeber, Lawrence Herz, Kong Kwon, William Lawson, Felicitas Mena, Javaid Sheikh, David Smelson, and Valerie Smith-Gamble
JAMA. 2003;290(20):2693-2702.
ABSTRACT | FULL TEXT